Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...
The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 ...
Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...
Onco-Innovations’ licensed technology demonstrates promise to enhance chemotherapy effectiveness by overcoming cancer cell resistance: Vancouver, BC Saturday, February 1, 2025, ...
The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...
Onco-Innovations Limited has announced promising results from its licensed technology of PNKP inhibitors, which enhance the ...
Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing of the first patient in the 5-STAR 1-01 Phase I/IIa trial (NCT06657222). The ...
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
The Phase I trial will evaluate the safety and efficacy of the company’s drug which targets tumours whilst leaving normal ...
Innate Pharma (IPHA) announced the first patient was dosed in its Phase 1 study, investigating the safety and tolerability of IPH4502, an ...
Aromatase is an enzyme that converts testosterone to estradiol, a type of estrogen. One study found that taking an estrogen blocker called an aromatase inhibitor while on testosterone therapy reduced ...
Immune checkpoint inhibitors (ICIs) have revolutionized treatment for several tumor indications without demonstrated benefit for ovarian cancer patients. To improve the therapeutic ratio of ICIs in ...